Literature DB >> 21132565

Hughes syndrome (the antiphospholipid syndrome): a disease of our time.

Graham R V Hughes1.   

Abstract

A pro-thrombotic condition was described in 1983 which was characterised by the presence of circulating antiphospholipid antibodies, as well as peripheral thrombosis (e.g. DVT), a tendency to internal organ involvement, repeated miscarriage, and, occasionally, thrombocytopenia (aPL) (Hughes, Br Med J 287:1088-1089, 1983). Previously, there had been a number of observations, mainly in patients with lupus having "false positive" tests for syphilis, miscarriage and circulating lupus anticoagulants. The description in 1983 had three notable features (a) a detailed comprehensive clinical picture of the syndrome; (b) this description differed from other coagulopathies in showing a propensity for arterial thrombosis (e.g. stroke and heart attack); and (c) this was a syndrome quite independent from lupus. There are indications that the primary antiphospholipid syndrome will turn out to be more common than lupus, though this could still be a reflection of referral practice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21132565     DOI: 10.1007/s10787-010-0071-3

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  25 in total

Review 1.  Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis.

Authors:  Panayiotis D Ziakas; Matthaios Pavlou; Michael Voulgarelis
Journal:  Obstet Gynecol       Date:  2010-06       Impact factor: 7.661

2.  Clinical improvement in antiphospholipid syndrome after rituximab therapy.

Authors:  Rosemary Adamson; Shirish Sangle; Arvind Kaul; Graham R V Hughes; David P D'Cruz
Journal:  J Clin Rheumatol       Date:  2008-12       Impact factor: 3.517

3.  Antiphospholipid syndrome, migraine and stroke.

Authors:  Graham R V Hughes
Journal:  Lupus       Date:  2010-01-21       Impact factor: 2.911

4.  Thrombosis, abortion, cerebral disease, and the lupus anticoagulant.

Authors:  G R Hughes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-15

5.  Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia.

Authors:  P Nencini; M C Baruffi; R Abbate; G Massai; L Amaducci; D Inzitari
Journal:  Stroke       Date:  1992-02       Impact factor: 7.914

Review 6.  Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature.

Authors:  M J Cuadrado; M A Khamashta; A Ballesteros; T Godfrey; M J Simon; G R Hughes
Journal:  Medicine (Baltimore)       Date:  2000-01       Impact factor: 1.889

7.  Hughes syndrome (antiphospholipid syndrome) and myocardial infarction.

Authors:  Graham Hughes
Journal:  Int J Clin Pract       Date:  2010-06-09       Impact factor: 2.503

Review 8.  Migraine, memory loss, and "multiple sclerosis ". Neurological features of the antiphospholipid (Hughes') syndrome.

Authors:  G R V Hughes
Journal:  Postgrad Med J       Date:  2003-02       Impact factor: 2.401

9.  The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model.

Authors:  Miri Blank; Liat Anafi; Gisele Zandman-Goddard; Ilan Krause; Shlomit Goldman; Eliezer Shalev; Ricard Cervera; Josep Font; Mati Fridkin; Hans-Jurgen Thiesen; Yehuda Shoenfeld
Journal:  Int Immunol       Date:  2007-06-18       Impact factor: 4.823

10.  Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension.

Authors:  S R Sangle; D P D'Cruz; W Jan; M Y Karim; M A Khamashta; I C Abbs; G R V Hughes
Journal:  Ann Rheum Dis       Date:  2003-10       Impact factor: 19.103

View more
  1 in total

1.  Leg ulcers in antiphospholipid syndrome secondary to systemic lupus erythematosus treated with intravenous immunoglobulin.

Authors:  Guida Santos; Alexandre João; Lourdes Sousa
Journal:  J Dermatol Case Rep       Date:  2014-06-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.